Amplyx Pharmaceuticals, Inc

@AmplyxPharma

Developing antifungal agents for the treatment of life-threatening invasive fungal infections due to Candida, Aspergillus and rare molds.

San Diego, CA
Vrijeme pridruživanja: svibanj 2019.

Medijski sadržaj

  1. Drug-Resistant Candida auris is now recognized as an URGENT Threat by the CDC, with an increasing number of strains resistant to all available therapies. New classes of antifungal therapies are needed!

  2. We are excited to add MAU868 to our development pipeline. MAU868 has the potential to be the first antiviral treatment for BKV disease which can affect Renal and Bone Marrow Transplant patients. Learn more at

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·